转化生长因子-β1在乙型肝炎病毒感染相关肝病发病中的作用研究进展

doi:10.3969/j.issn.1672-5069.2014.02.027

Abstract

Abstract: Transforming growth factor-β1 （TGF-β1） is a kind of cytokine with broad biological functions. It induces abnormality in cell number and function of immune cells and results in chronic infection of hepatitis B virus （HBV）；At the same time，TGF-β1 inhibits HBV replication through different ways；TGF-β1 also promotes liver fibrosis，affects hepatocellular carcinoma in a dual manner，and plays a significant role in the development of liver failure.

Key words: Hepatitis B, Transforming growth factor-β1, Liver fibrosis, Hepatocellular carcinoma, Liver failure

Xu Chao， Ma Yong.. Pathogenesis effects of transforming growth factor-β1 in hepatitis B virus infection-related liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 206-209.

References

[1] Rahimi RA，Leof EB. TGF-β signaling:A tale of two responses. J Cell Biochem，2007，102（3）:593-608.
[2] Verrecchia F，Mauviel A. Transfoming growth factor-beta and fibrosis. World J Gastroenterol，2007，13（22）:3056-3062.
[3] Palmer EM，Beilfuss BA，Naqai T，et al. Human helper T cell activation and differentiation is suppressed by porcine small intestinal submucosa. Tissue Eng，2002，8（5）:893-900.
[4] 刘晓霞，李凤鸣，陈育民，等. 转化生长因子β1对人外周血T淋巴细胞体外增殖及活化的影响. 实用医学杂志，2009，25（20）:3373-3375.
[5] Ai HB，Lin MF，Cen H，et al. TGF β1 inhibits the maturation of dendritic cells and down-regulates TLR4 expression. Chin J Pathophysiol，2005，21（8）:1476-1479.
[6] Sun C，Fu B，Gao Y，et al. TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog，2012，8（3）:e1002594.
[7] Manea I，Manea CN，Miron N，et al. Immunological aspects in viral hepatitis B and C infection. Roum Arch Microbiol Immunol，2011，70（3）:97-100.
[8] Flisiak R，Al-Kadasi H，Jaroszewicz J，et al. Effect of lamivudine treatment on plasma levels of transforming growth factor beta1，tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World J Gastroenterol，2004，10（18）:2661-2665.
[9] 肖寒，马陈斌，张利霞，等. 恩替卡韦对慢性乙型肝炎患者血清中HBV DNA载量与TGF-β1的影响. 南方医科大学学报， 2012，32（4）:589-592.
[10] Chou YC，Chen ML，Hu CP，et al. Transforming growth factor-beta1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA. Hepatology，2007，46（3）:672-681.
[11] Reese V，Ondracek C，Rushing C，et al. Multiple nuclear receptors may regulate hepatitis B virus biosynthesis during development. Int J Biochem Cell Biol，2011，43（2）:230-237.
[12] He F，Chen EQ，Liu L，et al. Inhibition of hepatitis B Virus replication by hepatocyte nuclear factor 4-alpha specific short hairpin RNA. Liver Int，2012，32（5）:742-751.
[13] Hong MH，Chou YC，Wu YC，et al. Transforming growth factor-β1 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4α expression. PLoS One，2012，7（1）: e30360.
[14] 雷瑞祥，陈燕，谢霞，等. 原蛋白转化酶在转化生长因子β-1抑制HBV复制效应中的作用. 中国病理生理杂志，2010，26（7）:1331-1334.
[15] Akpolat N，Yahsi S，Godekmerdan A，et al. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol，2005，11（21）:3260-3263.
[16] Moreno S，Garcia-Samaniego J，Moreno A，et al. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. Viral Hepat，2009，16（4）: 249-258.
[17] Nakamura T，Ueno T，Sakamoto M，et al. Suppression of transforming growth factor-beta results in upregulation of transcription of regeneration factors after chronic liver injury. J Hepatol，2004，41（6）:974-982.
[18] Du SS，Qiang M，Zeng ZC，et al. Radiation-induced liver fibrosis is mitigated by gene therapy inhibiting transforming growth factor-β signaling in the rat. Int J Radiat Oncol Biol Phys，2010，78（5）:1513-1523.
[19] Gnainsky Y，Kushnirsky Z，Bilu G，et al． Gene expression during chemically induced liver fibrosis:effect of halofuginone on TGF-beta signaling. Cell Tissue Res，2007，328（1）:153-166．
[20] Lang Q，Liu Q，Xu N，et al. The antifibrotic effects of TGF-β1 siRNA on hepatic fibrosis in rats. Biochem Biophys Res Commun，2011，409（3）:448-453.
[21] Tsai WL，Chung RT. Viral hepatocarcinogenesis. Oncegene， 2010，29（16）:2309-2324.
[22] Mamiya T，Yamazaki K，Masugi Y，et al. Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. Lab Invest，2010，90（9）:1339-1345.
[23] Dong ZZ，Yao DF，Yao M，et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int，2008，7（3）:288-295.
[24] Ceballos MP，Parody JP，Alvarez Mde L，et al. Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines:Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma Biochem Pharmacol，2011，82（11）:1682-1691.
[25] Morris SM，Baek JY，Koszarek A，et al. TGF-β signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology，2011，55（1）:121-131．
[26] Yang XH，Yamagiwa S，Ichida T，et al. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol，2006，45（2）:254-262.
[27] Feng X，Li B，Ye H，et al. Increased frequency of CD4+CD25（high） FoxP3+ regulatory T cells in patients with hepatocellular carcinoma. Arch Immunol Ther Exp（Warsz），2011，59（4）: 309-314.
[28] Park J，Lee J，Kang W，et al. TGF-β1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death. Cell Death Dis，2013，4:e521.
[29] Jin W，Yun C，Kwak MK，et al. TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling. Oncogene 2007，26（55）:7684-7691.
[30] Mamiya T，Yamazaki K，Masugi Y，et al. Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. Lab Invest，2010，90（9）:1339-1345.
[31] Pérez-Gómez E，Del Castillo G，Juan Francisco S，et al. The role of the TGF-β coreceptor endoglin in cancer. Sci World J， 2010，10:2367-2384.
[32] 江敏华，甘建和，罗二平，等. 肝衰竭患者血清TGF-β1的变化及临床意义. 江苏医药，2003，29（6）:435-436.
[33] Akpolat N，Yahsi S，Godekmerdan A，et al. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol，2005，11（21）:3260-3263.
[34] Antoniades CG，Quaqlia A，Taams LS，et al. Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. Hepatology，2012，56（2）:735-746.
[35] 陈文，邓存良，孙庆，等. 肝衰竭患者血清对大鼠库普弗细胞表达转化生长因子-β1的影响. 广东医学，2012，33（19）:2885-2887.

Pathogenesis effects of transforming growth factor-β1 in hepatitis B virus infection-related liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[8]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[9]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[10]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[11]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[12]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[13]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[14]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[15]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.